OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the ...

KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months ...

A Vanderbilt-led research team has made a significant breakthrough in developing advanced dialysis membranes using atomically thin materials like graphene. These innovative membranes, called ...

Yale researchers have created "Ochre," a genomically recoded organism that enables the production of synthetic proteins with ...

NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...

Despite regulatory challenges, the USA remains a very attractive markets for fintech innovation due to its ability to balance ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Researchers have identified the mitochondrial calcium uniporter as a critical protein in the strengthening of synaptic ...

New research uses AI to engineer enzymes with intricate active sites, expanding the possibilities for synthetic biocatalysts.

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...

The upcoming Future Food-Tech Summit, set to take place in San Francisco on March 13-14, 2025, will feature 61 startups and scale-ups presenting innovations ...